Abstract
Abstract This chapter offers an overview of the major scientific advances that led to the founding of the biotech industry in the 1970s. While the first entrepreneurial life-sciences companies were established primarily to take advantage of rDNA and monoclonal antibody technology, the chapter also highlights a number of other promising technologies, including antisense and gene therapy. It also shows how large pharmaceutical companies have adopted the same technologies. At the same time, biotech companies have branched out into the medicinal chemistry that has been the mainstay of the pharmaceutical industry. It explains that what distinguishes a biotech company from a large pharmaceutical company is not a focus on using any specific technology but the fact that the biotech company is smaller, newer, less experienced, and almost always unprofitable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
